Jan A, Sofi S, Jan N, Mir M
Future Oncol. 2025; 21(6):715-735.
PMID: 39936282
PMC: 11881842.
DOI: 10.1080/14796694.2025.2461443.
Huang J, Zhen W, Ma X, Ge S, Ma L
J Clin Biochem Nutr. 2025; 76(1):25-34.
PMID: 39896160
PMC: 11782780.
DOI: 10.3164/jcbn.23-131.
Ouyang M, Gui Y, Li N, Zhao L
Sci Rep. 2024; 14(1):30855.
PMID: 39730613
PMC: 11680876.
DOI: 10.1038/s41598-024-81503-x.
Krawczynska N, Wang Y, Lim K, Das Gupta A, Lenczowski A, Abughazaleh M
bioRxiv. 2024; .
PMID: 39131340
PMC: 11312600.
DOI: 10.1101/2024.08.02.606061.
Wan X, Shi W, Ma L, Wang L, Zheng R, He J
Clin Transl Med. 2024; 14(5):e1681.
PMID: 38725048
PMC: 11082093.
DOI: 10.1002/ctm2.1681.
Harnessing the potential of long non-coding RNAs in breast cancer: from etiology to treatment resistance and clinical applications.
Wang Y, Bu N, Luan X, Song Q, Ma B, Hao W
Front Oncol. 2024; 14:1337579.
PMID: 38505593
PMC: 10949897.
DOI: 10.3389/fonc.2024.1337579.
A promising target for breast cancer: B7-H3.
Jiang Y, Liu J, Chen L, Qian Z, Zhang Y
BMC Cancer. 2024; 24(1):182.
PMID: 38326735
PMC: 10848367.
DOI: 10.1186/s12885-024-11933-3.
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M
Mol Cancer. 2023; 22(1):172.
PMID: 37853437
PMC: 10583419.
DOI: 10.1186/s12943-023-01877-w.
Roles of salt‑inducible kinases in cancer (Review).
Feng S, Wei F, Shi H, Chen S, Wang B, Huang D
Int J Oncol. 2023; 63(5).
PMID: 37654200
PMC: 10546379.
DOI: 10.3892/ijo.2023.5566.
SPDEF enhances cancer stem cell-like properties and tumorigenesis through directly promoting GALNT7 transcription in luminal breast cancer.
Li J, Wan X, Xie D, Yuan H, Pei Q, Luo Y
Cell Death Dis. 2023; 14(8):569.
PMID: 37633945
PMC: 10460425.
DOI: 10.1038/s41419-023-06098-z.
Analysis of Differential Gene Expression and Core Canonical Pathways Involved in the Epithelial to Mesenchymal Transition of Triple Negative Breast Cancer Cells by Ingenuity Pathway Analysis.
Cagle E, Lake B, Banerjee A, Cuffee J, Banerjee N, Gilmartin D
Comput Mol Biosci. 2023; 13(2):21-34.
PMID: 37538932
PMC: 10398793.
DOI: 10.4236/cmb.2023.132002.
Vaccines in Breast Cancer: Challenges and Breakthroughs.
Fatima G, Fatma H, Saraf S
Diagnostics (Basel). 2023; 13(13).
PMID: 37443570
PMC: 10340541.
DOI: 10.3390/diagnostics13132175.
Downregulation of the long noncoding RNA DSCR9 (Down syndrome critical region 9) delays breast cancer progression by modulating microRNA-504-5p-dependent G protein-coupled receptor 65.
Li M, Lin C, Cai Z
Hum Cell. 2023; 36(4):1516-1534.
PMID: 37248366
DOI: 10.1007/s13577-023-00916-4.
Role of Escin in breast cancer therapy: potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin.
Li C, He Z, Yao F, Liao S, Sun K, Sun S
Apoptosis. 2023; 28(7-8):1154-1167.
PMID: 37149513
PMC: 10333422.
DOI: 10.1007/s10495-023-01849-x.
Role of RUNX2 in breast cancer development and drug resistance (Review).
Si W, Kan C, Zhang L, Li F
Oncol Lett. 2023; 25(5):176.
PMID: 37033103
PMC: 10079821.
DOI: 10.3892/ol.2023.13762.
eIF2Bδ blocks the integrated stress response and maintains eIF2B activity and cancer metastasis by overexpression in breast cancer stem cells.
Gupta M, Walters B, Katsara O, Granados Blanco K, Geter P, Schneider R
Proc Natl Acad Sci U S A. 2023; 120(15):e2207898120.
PMID: 37014850
PMC: 10104532.
DOI: 10.1073/pnas.2207898120.
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer.
Zhu X, Bu J, Zhu T, Jiang Y
J Transl Med. 2023; 21(1):184.
PMID: 36895039
PMC: 9996895.
DOI: 10.1186/s12967-023-04030-9.
PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway.
Zhang R, Dong M, Tu J, Li F, Deng Q, Xu J
Signal Transduct Target Ther. 2023; 8(1):97.
PMID: 36859354
PMC: 9977784.
DOI: 10.1038/s41392-023-01337-3.
The oncogenic and immunological roles of histidine triad nucleotide-binding protein 1 in human cancers and their experimental validation in the MCF-7 cell line.
Wang X, Zhou M, Jiang L
Ann Transl Med. 2023; 11(3):147.
PMID: 36846002
PMC: 9951023.
DOI: 10.21037/atm-22-6637.
Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.
Lv Y, Bai Z, Wang X, Liu J, Li Y, Zhang X
Sci Rep. 2022; 12(1):20524.
PMID: 36443508
PMC: 9705306.
DOI: 10.1038/s41598-022-25059-8.